A Phase II, Single-Arm, Multicenter Trial of BGB-A317 as a Second-Line Treatment for Patients with Previously Treated, PD-L1-Positive, Locally Advanced or Metastatic Urothelial Cancer (UC)
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 07 Nov 2018
At a glance
- Drugs Tislelizumab (Primary)
- Indications Bladder cancer; Urogenital cancer
- Focus Registrational; Therapeutic Use
- Sponsors BeiGene
- 07 Nov 2018 Status changed from recruiting to active, no longer recruiting, as reported in the BeiGene media release.
- 28 Feb 2018 According to a BeiGene media release, enrollment completion is expected in 2018.
- 07 Jul 2017 New trial record